US Drug Recall Register

FDA Drug Recalls

17,898 recalls, newest first

Class II · Moderate risk Terminated

Cardioplegia Solution

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-0002-1 D-0649-2023
Class II · Moderate risk Terminated

Microplegia

Reason Lack of Assurance of Sterility: after an FDA inspection called into question the sterility of the products intended to be sterile.

Central Admixture Pharmacy Services, Inc. NDC 71285-0001-1 D-0648-2023
Class III · Low risk Terminated

Fentanyl Buccal Tablets CII

Reason Labeling: Incorrect or Missing Package Insert

Teva Pharmaceuticals USA Inc NDC 51862-638-28 D-0770-2023
Class III · Low risk Terminated

Fentanyl Buccal Tablets CII

Reason Labeling: Incorrect or Missing Package Insert

Teva Pharmaceuticals USA Inc NDC 51862-637-28 D-0769-2023
Class III · Low risk Terminated

Fentanyl Buccal Tablets CII

Reason Labeling: Incorrect or Missing Package Insert

Teva Pharmaceuticals USA Inc NDC 51862-636-28 D-0768-2023
Class III · Low risk Terminated

Fentanyl Buccal Tablets CII

Reason Labeling: Incorrect or Missing Package Insert

Teva Pharmaceuticals USA Inc NDC 51862-635-28 D-0767-2023
Class III · Low risk Terminated

Fentanyl Buccal Tablets CII

Reason Labeling: Incorrect or Missing Package Insert

Teva Pharmaceuticals USA Inc NDC 51862-634-28 D-0766-2023
Class II · Moderate risk Ongoing

Tropicamide Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0864-2023
Class II · Moderate risk Ongoing

Ropivacaine Hydrochloride Injection USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0863-2023
Class II · Moderate risk Ongoing

Olopatadine HCl Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0860-2023
Class II · Moderate risk Ongoing

Midazolam Injection

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0859-2023
Class II · Moderate risk Ongoing

Calcitriol Injection 2 mcg/mL

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0858-2023
Class II · Moderate risk Ongoing

Amantadine Hydrochloride Oral Solution USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0857-2023
Class II · Moderate risk Ongoing

Xopenex

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0856-2023
Class II · Moderate risk Ongoing

Vitamin D Supplement Drops

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0855-2023
Class II · Moderate risk Ongoing

Valproic Acid Oral Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0854-2023
Class II · Moderate risk Ongoing

Tropicamide Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0853-2023
Class II · Moderate risk Ongoing

Tobramycin Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0851-2023
Class II · Moderate risk Ongoing

Tobramycin Inhalation Solution USP

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0850-2023
Class II · Moderate risk Ongoing

Timolol Maleate Ophthalmic Solution

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0849-2023
Class II · Moderate risk Ongoing

Sufenta

Reason CGMP Deviations: Firm went out of business and could no longer continue stability studies.

Akorn, Inc. D-0847-2023